Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Johnson and Johnson
US Army
Dow
Baxter
Julphar
Fish and Richardson
Cipla
Cantor Fitzgerald
McKinsey

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020379

« Back to Dashboard

NDA 020379 describes CAVERJECT, which is a drug marketed by Pfizer and Pharmacia And Upjohn and is included in three NDAs. It is available from one supplier. Additional details are available on the CAVERJECT profile page.

The generic ingredient in CAVERJECT is alprostadil. There are seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the alprostadil profile page.
Summary for 020379
Pharmacology for NDA: 020379
Medical Subject Heading (MeSH) Categories for 020379
Suppliers and Packaging for NDA: 020379
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CAVERJECT alprostadil INJECTABLE;INJECTION 020379 NDA Pharmacia and Upjohn Company LLC 0009-3701 N 0009-3701-05
CAVERJECT alprostadil INJECTABLE;INJECTION 020379 NDA Pharmacia and Upjohn Company LLC 0009-7686 N 0009-7686-04

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength0.01MG/VIAL
Approval Date:Jul 6, 1995TE:APRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength0.02MG/VIAL
Approval Date:Jul 6, 1995TE:APRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength0.005MG/VIAL
Approval Date:Jun 27, 1996TE:RLD:Yes

Expired US Patents for NDA 020379

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pharmacia And Upjohn CAVERJECT alprostadil INJECTABLE;INJECTION 020379-001 Jul 6, 1995 ➤ Sign Up ➤ Sign Up
Pharmacia And Upjohn CAVERJECT alprostadil INJECTABLE;INJECTION 020379-002 Jul 6, 1995 ➤ Sign Up ➤ Sign Up
Pharmacia And Upjohn CAVERJECT alprostadil INJECTABLE;INJECTION 020379-003 Jun 27, 1996 ➤ Sign Up ➤ Sign Up
Pharmacia And Upjohn CAVERJECT alprostadil INJECTABLE;INJECTION 020379-004 May 19, 1997 ➤ Sign Up ➤ Sign Up
Pharmacia And Upjohn CAVERJECT alprostadil INJECTABLE;INJECTION 020379-001 Jul 6, 1995 ➤ Sign Up ➤ Sign Up
Pharmacia And Upjohn CAVERJECT alprostadil INJECTABLE;INJECTION 020379-002 Jul 6, 1995 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Johnson and Johnson
Citi
Boehringer Ingelheim
Argus Health
Express Scripts
Dow
UBS
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot